Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene
Differential effects of clinically-relevant N- vs C-terminal truncating CDKN1A mutations on cisplatin sensitivity in bladder cancer.
Sikder RK, Ellithi M, Uzzo RN, Weader D, Metz AL, Behbahani A, McKenzie ER, El-Deiry WS, Abbosh PH
Mol Cancer Res. 2020 Dec 3. pii: 1541-7786.MCR-19-1200. doi: 10.1158/1541-7786.MCR-19-1200. PubMed Article

Plasmids from Article

ID Plasmid Purpose
78852pLentiCRISPR-EIntroduce sgRNA into a lentiviral vector (LentiCRISPR V2) which contains eSpCas9 and puromycin cassette

Antibodies from Article